Healthcare - Biotechnology - NASDAQ - US
$ 2.5
-6.72 %
$ 4.94 M
Market Cap
-0.22
P/E
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.[ Read More ]
The intrinsic value of one ATNF stock under the base case scenario is HIDDEN Compared to the current market price of 2.5 USD, 180 Life Sciences Corp. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart ATNF
FINANCIALS
0
REVENUE
-13.5 M
OPERATING INCOME
-19.9 M
NET INCOME
-10.9 M
OPERATING CASH FLOW
0
INVESTING CASH FLOW
5.91 M
FINANCING CASH FLOW
0
REVENUE
-979 K
OPERATING INCOME
-837 K
NET INCOME
-224 K
OPERATING CASH FLOW
0
INVESTING CASH FLOW
-476 K
FINANCING CASH FLOW
Balance Sheet Decomposition
180 Life Sciences Corp.
| Current Assets | 3.64 M |
| Cash & Short-Term Investments | 1.98 M |
| Receivables | 0 |
| Other Current Assets | 1.66 M |
| Non-Current Assets | 1.62 M |
| Long-Term Investments | 0 |
| PP&E | 0 |
| Other Non-Current Assets | 1.62 M |
| Current Liabilities | 5.06 M |
| Accounts Payable | 2.16 M |
| Short-Term Debt | 1.03 M |
| Other Current Liabilities | 1.87 M |
| Non-Current Liabilities | 325 K |
| Long-Term Debt | 19.9 K |
| Other Non-Current Liabilities | 305 K |
EFFICIENCY
Earnings Waterfall
180 Life Sciences Corp.
| Revenue | 0 |
| Cost Of Revenue | 106 K |
| Gross Profit | -106 K |
| Operating Expenses | 13.4 M |
| Operating Income | -13.5 M |
| Other Expenses | 6.46 M |
| Net Income | -19.9 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
15606.86%
ROE
-379.03%
ROA
153390000.83%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
180 Life Sciences Corp.
| Net Income | -19.9 M |
| Depreciation & Amortization | 106 K |
| Capital Expenditures | 3 |
| Stock-Based Compensation | 2.28 M |
| Change in Working Capital | -14.1 K |
| Others | 8.69 M |
| Free Cash Flow | -10.9 M |
Wall Street Analysts Price Targets
180 Life Sciences Corp.
ATNF has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
180 Life Sciences Corp.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
4.7 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
4.7 K USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
11 months ago
Dec 15, 2023
|
Sell 4.7 K USD
|
Feldmann Marc
Director |
- 25000
|
0.188 USD |
|
11 months ago
Dec 15, 2023
|
Bought 4.7 K USD
|
Woody James N.
Chief Executive Officer |
+ 25000
|
0.188 USD |
|
1 year ago
Jun 01, 2023
|
Bought 22.1 K USD
|
STEINMAN LAWRENCE
Director |
+ 18000
|
1.226 USD |
|
1 year ago
May 31, 2023
|
Bought 11.5 K USD
|
McGovern Jr. Donald A.
Director |
+ 10000
|
1.147 USD |
|
1 year ago
May 19, 2023
|
Bought 5.8 K USD
|
McGovern Jr. Donald A.
Director |
+ 5000
|
1.16 USD |
|
1 year ago
May 18, 2023
|
Bought 10.5 K USD
|
McGovern Jr. Donald A.
Director |
+ 10000
|
1.05 USD |
|
1 year ago
May 18, 2023
|
Bought 7.51 K USD
|
Marrone Pamela G
Director |
+ 7082.019
|
1.06 USD |
|
1 year ago
May 18, 2023
|
Bought 5.21 K USD
|
Pamir Ozan
CFO |
+ 5162.077
|
1.01 USD |
|
1 year ago
May 18, 2023
|
Bought 41.2 K USD
|
Woody James N.
Chief Executive Officer |
+ 40000
|
1.03 USD |
|
2 years ago
Dec 16, 2021
|
Bought 31.8 K USD
|
Vu Quan Anh
COO / Chief Business Officer |
+ 8000
|
3.98 USD |
|
2 years ago
Dec 09, 2021
|
Bought 204 K USD
|
Feldmann Marc
Director |
+ 50000
|
4.07 USD |
|
2 years ago
Dec 09, 2021
|
Bought 20 K USD
|
DeLuca Teresa
Director |
+ 5000
|
4 USD |
|
2 years ago
Dec 09, 2021
|
Bought 9.95 K USD
|
DeLuca Teresa
Director |
+ 2500
|
3.98 USD |
|
2 years ago
Dec 09, 2021
|
Bought 9.98 K USD
|
DeLuca Teresa
Director |
+ 2500
|
3.99 USD |
|
2 years ago
Dec 09, 2021
|
Bought 9.88 K USD
|
DeLuca Teresa
Director |
+ 2500
|
3.95 USD |
|
2 years ago
Dec 10, 2021
|
Bought 14.7 K USD
|
Pamir Ozan
Interim CFO |
+ 3800
|
3.87 USD |
|
2 years ago
Dec 10, 2021
|
Bought 4.1 K USD
|
Marrone Pamela G
Director |
+ 1000
|
4.1 USD |
|
2 years ago
Dec 10, 2021
|
Bought 17.6 K USD
|
Vu Quan Anh
COO / Chief Business Officer |
+ 4500
|
3.9 USD |
|
2 years ago
Dec 09, 2021
|
Bought 53.4 K USD
|
Woody James N.
Chief Executive Officer |
+ 12500
|
4.27 USD |
|
2 years ago
Dec 09, 2021
|
Bought 21.3 K USD
|
STEINMAN LAWRENCE
Director |
+ 5000
|
4.27 USD |
|
2 years ago
Dec 09, 2021
|
Bought 103 K USD
|
McGovern Jr. Donald A.
Director |
+ 25000
|
4.13 USD |
|
3 years ago
Dec 14, 2020
|
Sell 24.5 K USD
|
KRAUSS MARLENE
10 percent owner |
- 10000
|
2.45 USD |
|
3 years ago
Dec 15, 2020
|
Sell 42.9 K USD
|
KRAUSS MARLENE
10 percent owner |
- 17877
|
2.4 USD |
|
3 years ago
Dec 17, 2020
|
Sell 10.7 K USD
|
KRAUSS MARLENE
10 percent owner |
- 4403
|
2.44 USD |
|
3 years ago
Dec 17, 2020
|
Sell 30.1 K USD
|
KRAUSS MARLENE
10 percent owner |
- 12103
|
2.49 USD |
|
4 years ago
Nov 17, 2020
|
Sell 7.45 K USD
|
KRAUSS MARLENE
10 percent owner |
- 3300
|
2.2562 USD |
|
3 years ago
Nov 18, 2020
|
Sell 15.5 K USD
|
KRAUSS MARLENE
10 percent owner |
- 6700
|
2.3105 USD |
|
3 years ago
Nov 19, 2020
|
Sell 70.8 K USD
|
KRAUSS MARLENE
10 percent owner |
- 33445
|
2.118 USD |
|
3 years ago
Nov 23, 2020
|
Sell 198 K USD
|
KRAUSS MARLENE
10 percent owner |
- 60633
|
3.2602 USD |
|
3 years ago
Nov 25, 2020
|
Sell 33.8 K USD
|
KRAUSS MARLENE
10 percent owner |
- 12182
|
2.7753 USD |
|
4 years ago
Nov 09, 2020
|
Bought 3.29 K USD
|
Woody James N.
Chief Executive Officer |
+ 1000
|
3.2895 USD |
|
5 years ago
Oct 09, 2019
|
Sell 4.2 M USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 400000
|
10.51 USD |
|
5 years ago
Oct 09, 2019
|
Sell 3.15 M USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 299900
|
10.5 USD |
|
5 years ago
Oct 03, 2019
|
Sell 1.05 K USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 100
|
10.52 USD |
|
5 years ago
Sep 24, 2019
|
Sell 1.2 M USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 113937
|
10.5 USD |
|
5 years ago
Sep 12, 2019
|
Sell 265 K USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 25260
|
10.5 USD |
|
5 years ago
Sep 09, 2019
|
Sell 42 K USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 3999
|
10.51 USD |
|
5 years ago
Aug 30, 2019
|
Sell 62 K USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 5900
|
10.5 USD |
|
5 years ago
Aug 16, 2019
|
Sell 2.1 M USD
|
MIZUHO SECURITIES USA LLC
10 percent owner |
- 200000
|
10.48 USD |
|
5 years ago
Aug 14, 2019
|
Sell 1.57 M USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 150004
|
10.49 USD |
|
5 years ago
Aug 07, 2019
|
Sell 71.6 K USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 6800
|
10.53 USD |
|
5 years ago
Aug 05, 2019
|
Sell 2.11 K USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 200
|
10.53 USD |
|
5 years ago
Jul 24, 2019
|
Sell 1.05 K USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 100
|
10.49 USD |
|
5 years ago
Jun 20, 2019
|
Sell 6.29 K USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 600
|
10.48 USD |
|
5 years ago
Jun 14, 2019
|
Sell 3.14 K USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 300
|
10.48 USD |
|
5 years ago
Jun 10, 2019
|
Sell 4.56 K USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 435
|
10.48 USD |
|
5 years ago
May 29, 2019
|
Sell 5.24 K USD
|
OXFORD ASSET MANAGEMENT LLP
10 percent owner |
- 500
|
10.48 USD |
|
7 years ago
Jun 27, 2017
|
Sell 121 K USD
|
Polar Asset Management Partners Inc.
10 percent owner |
- 12500
|
9.7 USD |
|
7 years ago
Jun 23, 2017
|
Bought 275 K USD
|
KRAUSS MARLENE
Chief Executive Officer |
+ 27500
|
10 USD |
|
7 years ago
Jun 07, 2017
|
Bought 3.5 M USD
|
KRAUSS MARLENE
Chief Executive Officer |
+ 350000
|
10 USD |
7. News
180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors
PALO ALTO, CA / ACCESSWIRE / October 29, 2024 / 180 Life Sciences Corp. ("180" or the "Company") (NASDAQ:ATNF) today announced the appointment of Mr. Jay Goodman to its Board of Directors, effective immediately.
accesswire.com
- 2 weeks ago
180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform
PALO ALTO, CA / ACCESSWIRE / October 16, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF)("180" or the "Company"), today released the following letter to stockholders from its Interim Chief Executive Officer, Blair Jordan. Dear Stockholders: We are excited to announce that 180 is planning to strategically enter into the online gaming industry, utilizing its newly acquired "back-end" gaming platform, which incorporates blockchain technology and full cryptocurrency operability (the "Gaming Technology Platform").
accesswire.com
- 1 month ago
180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector
PALO ALTO, CA / ACCESSWIRE / October 9, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180"), is pleased to announce that it has received confirmation from Nasdaq that the Company has officially regained compliance with Nasdaq Listing Rule 5550(b)(1), which requires a minimum stockholders' equity of $2,500,000. With this important achievement, the Company can now fully focus on developing its newly announced iGaming business, while also continuing to advance its legacy biotechnology programs.
accesswire.com
- 1 month ago
180 Life Sciences Corp. - Corporate Updates
Announcing Acquisition of Advanced Gaming Technology Platform, Positive Progress on Legacy CBD Formulation, and Strengthened Balance Sheet PALO ALTO, CA / ACCESSWIRE / October 3, 2024 / 180 Life Sciences Corp. (NASDAQ:ATNF) (the "Company" or "180") is pleased to provide a corporate update covering several key initiatives. CORPORATE UPDATE HIGHLIGHTS: Company shifts focus and enters global iGaming market - completes a significant technology acquisition Expected Compliance with Nasdaq Listing Rule 5550(b)(1) - Company expects to meet Nasdaq continued listing requirement which requires maintenance of stockholders' equity of at least $2.5 million Positive Study Results on CBD Pill Forms - 180 achieves promising study results showing faster absorption and improved bioavailability for its new CBD pill formulation Strengthened Balance Sheet - Company enhances its financial position by settling meaningful legacy liabilities at substantial discounts, improving its flexibility for future growth while at the same time resolving certain legacy litigation matters "We believe that this acquisition is a pivotal moment for the Company," said Blair Jordan, Interim CEO of 180, who continued, "We believe this transaction not only satisfies Nasdaq's minimum stockholder equity requirements for continued listing, but also sets the stage for the Company's entry into the dynamic and fast-growing global iGaming industry.
accesswire.com
- 1 month ago
180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer
PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (“180” or the “Company”) is pleased to announce the appointment of Omar Jimenez as its new Chief Financial Officer, effective September 30, 2024. Mr. Jimenez, already a director of the Company, will play a key role in driving the financial strategy of the Company as it continues to grow and innovate in the pharma and biotechnology sectors.
globenewswire.com
- 2 months ago
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced topline results from a clinical pharmacology study (the “Study”), that evaluated the uptake of cannabidiol (CBD) in a solid formulation which can be delivered as a pill orally. The clinical trial in humans, performed with Prof. Avi Domb of the Hebrew University, School of Pharmacy, and with Prof. Elyad Davidson, of Hadassah Hospital, compared two solid formulations of CBD with a U.S. Food and Drug Administration (FDA) approved drug for epilepsy, Epidiolex. The purpose of the Study was to compare the pharmokinetic (PK) profile of a generic approved CBD product, Epidiolex®, with two solid formulations. We believe this type of trial has yet to be examined in a clinical setting. For the Company's trial, twelve volunteers received all three formulations in a crossover randomized trial.
globenewswire.com
- 3 months ago
180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
PALO ALTO, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Hearings Panel has determined to grant the Company's request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions, including filing on or before July 31, 2024, a public disclosure describing the transactions undertaken by the Company to achieve compliance with Nasdaq's continued listing rules and demonstrate long-term compliance with the Equity Rule (defined below) and providing an indication of its equity following those transactions.
globenewswire.com
- 4 months ago
180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
PALO ALTO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”).
globenewswire.com
- 8 months ago
180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan
PALO ALTO, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-19 (the “Reverse Stock Split”). The Reverse Stock Split is expected to become effective on February 28, 2024 at 12:01 p.m. Eastern Time (the “Effective Time”), with shares expected to begin trading on the Nasdaq Capital Market, on a split-adjusted, at market open on February 28, 2024. In connection with the Reverse Stock Split, every 19 shares of the Company's common stock issued and outstanding as of the Effective Time will be automatically converted into one share of the Company's common stock. No change will be made to the trading symbol for the Company's shares of common stock or public warrants, “ATNF” and “ATNFW”, respectively, in connection with the reverse split.
globenewswire.com
- 8 months ago
180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives
PALO ALTO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced it has engaged A.G.P./Alliance Global Partners as financial advisor to explore and evaluate strategic alternatives to enhance shareholder value.
globenewswire.com
- 11 months ago
180 Life Sciences Announces Review of Strategic Alternatives
PALO ALTO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that its Board of Directors has initiated a process to evaluate potential strategic alternatives with the intent to unlock and maximize shareholder value. In consultation with financial and legal advisors, the Company intends to consider a broad range of strategic, operational and financial alternatives, and is exploring a full range of options.
globenewswire.com
- 11 months ago
180 Life Sciences Corp. Announces Closing of $3 Million Public Offering
PALO ALTO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF, “180 Life Sciences” or the “Company”), a clinical-stage biotechnology company, today announced the closing of its previously announced public offering of 4,615,385 shares of the Company's common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 4,615,385 shares of common stock at a purchase price per share (and accompanying warrant) of $0.65. The warrants are immediately exercisable at an exercise price of $0.65 per share and will expire October 10, 2028. The gross proceeds from the offering are approximately $3 million, before deducting the placement agent's fees and other offering expenses.
globenewswire.com
- 1 year ago
8. Profile Summary
180 Life Sciences Corp. ATNF
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 4.94 M
Dividend Yield
0.00%
Description
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Contact
Building 4, Palo Alto, CA, 94306
https://180lifesciences.com
IPO Date
June 27, 2017
Employees
4
Officers
Mr. Jason Assad
Director of IR
Prof. Jagdeep Nanchahal M.D., Ph.D.
Co-Founder & Chairman of Clinical Advisory Board
Sir Marc Feldmann Ph.D.
Co-Founder
Dr. Lawrence Steinman BA, M.D., Ph.D.
Co-Founder & Director